Phase 3 COPD trials recruiting now

All COPD trials, every phase

Other phases for COPD

Phase 3 COPD trials

• "The Effect of Inhaled Nitroglycerin for COPD Patients
  NCT06785337 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD
  NCT07583849 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 921 locations
• A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
  NCT07780669 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 2 locations
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 305 locations
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
  NCT06878261 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 276 locations
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07363694 · Phase: Phase 2, Phase 3 · Ages: 35 Years to 80 Years · Sex: All (male and female) · 120 locations
• Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination
  NCT07604103 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
  NCT04147286 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Cell Therapy Associated With Endobronchial Valve
  NCT04018729 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
  NCT06959095 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 15 locations
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
  NCT06961214 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 159 locations
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 221 locations
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 214 locations
• Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07039669 · Phase: Phase 3 · Ages: 40 Years to 85 Years · Sex: All (male and female) · 4 locations
• Expertise Asthma COPD Program with Digital Support
  NCT05831566 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
  NCT07566195 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 13 locations
• Multi-Center Clean Air Randomized Controlled Trial in COPD
  NCT06376994 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · 11 locations
• Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hypercapnic Respiratory Failure
  NCT07047092 · Phase: Phase 3 · Ages: 18 Years to 84 Years · Sex: All (male and female) · 1 location
• Reducing Breathlessness With Dronabinol in COPD Patients
  NCT06473701 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Supported Rescue Packs Post-discharge in Chronic Obstructive Pulmonary Disease
  NCT06347536 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · 34 locations
• Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease
  NCT05844462 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
  NCT06474039 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• Trial to Determine Effective Aspirin Dose in COPD
  NCT05265299 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · 1 location
• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
  NCT07177339 · Phase: Phase 3 · Ages: 40 Years to 75 Years · Sex: All (male and female) · 121 locations

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.